Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?
Immunocore Holdings (NASDAQ:IMCR) said May 31 it updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma, presented in a 2026 ASCO poster. The company reported a 6-month overall survival rate of 87% and a 52% disease control rate in HLA-A*02:01-positive patients, including those with primary PD-1 resistance, and reaffirmed Phase 3 PRISM-MEL-301 plans combining brenetafusp 160 mcg with nivolumab.
How this was made
The 30-second read
Why it matters
The new concrete datapoints (OS and disease control rates, including PD-1 resistance) are supportive for the program’s clinical narrative and can affect near-term trading and longer-term positioning for the Phase 3 read-through.
Market read
Traders may reassess IMCR’s probability-weighted outcomes for PRISM-MEL-301 based on updated efficacy signals, especially in PD-1–resistant patients.
What to watch
The article doesn’t provide safety/tolerability details, durability beyond 6 months, or comparative benchmarks—key items that can swing valuation even with positive response rates.
Background
The piece frames Immunocore’s brenetafusp Phase 1/2 melanoma results presented at the 2026 ASCO Annual Meeting and ties them to the ongoing Phase 3 PRISM-MEL-301 trial strategy.
Ticker impact
Immunocore reported updated Phase 1/2 brenetafusp data at ASCO, including 6-month OS and responses in PD-1–resistant melanoma.
Near-term upside bias for IMCR on trial-data optimism, with volatility tied to subsequent Phase 3 readouts.
The article provides specific efficacy metrics (6-month OS 87%, disease control 52%) and a management quote linking the data to confidence in the 160 mcg + nivolumab first-line strategy.
Market effects
Reinforces investor appetite for TCR bispecific immunotherapies and checkpoint-combination strategies in melanoma.
Limited direct regional spillover; primarily US small-cap biotech sentiment.
Melanoma immunotherapy efficacy signals can influence global biotech peer sentiment, but impact is company-specific here.
Counterpoint
Early Phase 1/2 efficacy and subgroup signals may not translate into Phase 3 success; investors could fade the optimism ahead of PRISM-MEL-301 milestones.
Key entities
- companyImmunocore Holdings plc
NASDAQ-listed biotech developing TCR bispecific immunotherapies; subject of the article’s trial-data update.
- drug_candidatebrenetafusp
TCR bispecific immunotherapy evaluated in Phase 1/2 for advanced melanoma; updated results cited.
- clinical_trialPRISM-MEL-301
Ongoing Phase 3 trial evaluating brenetafusp (160 mcg) in combination with nivolumab in first-line advanced melanoma.
